Minocycline as adjunct therapy for a male patient with deficit schizophrenia

References

• TuominenHJTiihonenJWahlbeckKGlutamatergic drugs for schizophrenia: a systematic review and meta-analysisSchizophr Res2005722–322523415560967
   PubMed Web of Science ®Google Scholar
• MurphyBPChungYCParkTWMcGorryPDPharmacological treatment of primary negative symptoms in schizophrenia: a systematic reviewSchizophr Res2006881–352516930948
   PubMed Web of Science ®Google Scholar
• ChenSLLeeSYChangYHInflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphanJ Neuroimmune Pharmacol20127365666422730040
   PubMed Web of Science ®Google Scholar
• MillerBJBuckleyPSeaboltWMellorAKirkpatrickBMeta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effectsBiol Psychiatry201170766367121641581
   PubMed Web of Science ®Google Scholar
• DengHKahlonRSMohiteSElevated plasma S100B, psychotic symptoms, and cognition in schizophreniaPsychiatr Q2018891536028435992
   PubMed Web of Science ®Google Scholar
• MonjiAKatoTKanbaSCytokines and schizophrenia: microglia hypothesis of schizophreniaPsychiatry Clin Neurosci200963325726519579286
   PubMed Web of Science ®Google Scholar
• WehringHJElsobkyTMcEvoyJPAdjunctive minocycline in clozapine-treated patients with schizophrenia: analyzing the effects of minocycline on clozapine plasma levelsPsychiatr Q2018891738028466366
   PubMed Web of Science ®Google Scholar
• Khodaie-ArdakaniMRMirshafieeOFarokhniaMMinocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled studyPsychiatry Res2014215354054624480077
   PubMed Web of Science ®Google Scholar
• KellerWRKumLMWehringHJKoolaMMBuchananRWKellyDLA review of anti-inflammatory agents for symptoms of schizophreniaJ Psychopharmacol201327433734223151612
   PubMed Web of Science ®Google Scholar
• MonjiAThe neuroinflammation hypothesis of psychiatric disordersSeishin Shinkeigaku Zasshi2012114212413322568115
   PubMedGoogle Scholar
• HashimotoKMicroglial activation in schizophrenia and minocycline treatmentProg Neuropsychopharmacol Biol Psychiatry20083271758175918652869
   PubMed Web of Science ®Google Scholar
• FilipovicRZecevicNNeuroprotective role of minocycline in co-cultures of human fetal neurons and microgliaExp Neurol20082111415118359018
   PubMed Web of Science ®Google Scholar
• KimSSKongPJKimBSSheenDHNamSYChunWInhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cellsArch Pharm Res200427331431815089037
   PubMed Web of Science ®Google Scholar
• LeeSMYuneTYKimSJMinocycline inhibits apoptotic cell death via attenuation of TNF-alpha expression following iNOS/NO induction by lipopolysaccharide in neuron/glia co-culturesJ Neurochem200491356857815485488
   PubMed Web of Science ®Google Scholar
• LevkovitzYLeviUBrawYCohenHMinocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophreniaBrain Res2007115415416217488642
   PubMed Web of Science ®Google Scholar
• ZhangLShirayamaYIyoMHashimotoKMinocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpineNeuropsychopharmacology20073292004201017228338
   PubMed Web of Science ®Google Scholar
• FujitaYIshimaTKunitachiSPhencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocyclineProg Neuropsychopharmacol Biol Psychiatry200832233633917884273
   PubMed Web of Science ®Google Scholar
• LiuFGuoXWuRMinocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trialSchizophr Res20141531–316917624503176
   PubMed Web of Science ®Google Scholar
• LevkovitzYMendlovichSRiwkesSA double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophreniaJ Clin Psychiatry201071213814919895780
   PubMed Web of Science ®Google Scholar
• ChaudhryIBHallakJHusainNMinocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatmentJ Psychopharmacol20122691185119322526685
   PubMed Web of Science ®Google Scholar
• JhamnaniKShivakumarVKalmadySRaoNPVenkatasubramanianGSuccessful use of add-on minocycline for treatment of persistent negative symptoms in schizophreniaJ Neuropsychiatry Clin Neurosci2013251E06E0723487204
   PubMed Web of Science ®Google Scholar
• MiyaokaTYasukawaRYasudaHHayashidaMInagakiTHoriguchiJPossible antipsychotic effects of minocycline in patients with schizophreniaProg Neuropsychopharmacol Biol Psychiatry200731130430717030375
   PubMed Web of Science ®Google Scholar
• CarpenterWTJrHeinrichsDWWagmanAMDeficit and non-deficit forms of schizophrenia: the conceptAm J Psychiatry198814555785833358462
   PubMed Web of Science ®Google Scholar
• GalderisiSMajMDeficit schizophrenia: an overview of clinical, biological and treatment aspectsEur Psychiatry200924849350019553087
   PubMed Web of Science ®Google Scholar
• Garcia-RizoCFernandez-EgeaEOliveiraCJusticiaABernardoMKirkpatrickBInflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit featuresPsychiatry Res2012198221221522405656
   PubMed Web of Science ®Google Scholar
• KirkpatrickBBuchananRWMcKenneyPDAlphsLDCarpenterWTJrThe schedule for the deficit syndrome: an instrument for research in schizophreniaPsychiatry Res19893021191232616682
   PubMed Web of Science ®Google Scholar
• AndreasenNCNegative symptoms in schizophrenia. Definition and reliabilityArch Gen Psychiatry19823977847887165477
   PubMed Web of Science ®Google Scholar
• KellyDLVyasGRichardsonCMAdjunct minocycline to clozapine treated patients with persistent schizophrenia symptomsSchizophr Res20111331–325725821872445
   PubMed Web of Science ®Google Scholar
• KellyDLSullivanKMMcEvoyJPAdjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptomsJ Clin Psychopharmacol201535437438126082974
   PubMed Web of Science ®Google Scholar
• MiyaokaTYasukawaRYasudaHHayashidaMInagakiTHoriguchiJMinocycline as adjunctive therapy for schizophrenia: an open-label studyClin Neuropharmacol200831528729218836347
   PubMed Web of Science ®Google Scholar
• LevauxMNPotvinSSepehryAASablierJMendrekAStipEComputerized assessment of cognition in schizophrenia: promises and pitfalls of CANTABEur Psychiatry200722210411517227707
   PubMed Web of Science ®Google Scholar
• LiZZhengBDengWLiuXZhengZLiTMulti-components of evoked-brain potentials in deficit and nondeficit schizophreniaAsia Pac Psychiatry201352697923857807
   PubMed Web of Science ®Google Scholar
• LiZDengWLiuXContingent negative variation in patients with deficit schizophrenia or bipolar I disorder with psychotic features: measurement and correlation with clinical characteristicsNord J Psychiatry201569319620325263850
   PubMed Web of Science ®Google Scholar
• LiZLeiWDengWAberrant spontaneous neural activity and correlation with evoked-brain potentials in first-episode, treatment-naïve patients with deficit and non-deficit schizophreniaPsychiatry Res Neuroimaging201726191928092779
   PubMed Web of Science ®Google Scholar
• LeuchtSPitschel-WalzGEngelRRKisslingWAmisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trialsAm J Psychiatry2002159218019011823257
   PubMed Web of Science ®Google Scholar
• RosenheckRDunnLPeszkeMImpact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory SchizophreniaAm J Psychiatry1999156188939892302
   PubMed Web of Science ®Google Scholar
• LindenmayerJPKhanAIskanderAAbadMTParkerBA randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophreniaJ Clin Psychiatry200768336837917388705
   PubMed Web of Science ®Google Scholar
• GirgisRRDiwadkarVANutcheJJSweeneyJAKeshavanMSHardanAYRisperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric studySchizophr Res2006821899416413757
   PubMed Web of Science ®Google Scholar
• KatoTMizoguchiYMonjiAInhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitroJ Neurochem2008106281582518429930
   PubMed Web of Science ®Google Scholar